Innate Pharma (IPH) - Total Liabilities
Based on the latest financial reports, Innate Pharma (IPH) has total liabilities worth €84.42 Million EUR (≈ $98.70 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Innate Pharma - Total Liabilities Trend (2003–2025)
This chart illustrates how Innate Pharma's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Innate Pharma to evaluate short-term liquidity relative to the company's equity base.
Innate Pharma Competitors by Total Liabilities
The table below lists competitors of Innate Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
John Hancock Investors Closed Fund
NYSE:JHI
|
USA | $90.58 Million |
|
ATW Technology Inc
TWO:8097
|
Taiwan | NT$146.69 Million |
|
Distribuidora de Gas Cuyana SA
BA:DGCU2
|
Argentina | AR$146.65 Billion |
|
C-Media Electronics
TWO:6237
|
Taiwan | NT$79.20 Million |
|
Eidesvik Offshore ASA
OL:EIOF
|
Norway | Nkr2.07 Billion |
|
Prime Office A/S
CO:PRIMOF
|
Denmark | Dkr2.64 Billion |
|
LK CHEM
KQ:489500
|
Korea | ₩6.53 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Innate Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Innate Pharma worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.77 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innate Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innate Pharma (2003–2025)
The table below shows the annual total liabilities of Innate Pharma from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €84.42 Million ≈ $98.70 Million |
-17.41% |
| 2024-12-31 | €102.22 Million ≈ $119.51 Million |
-22.73% |
| 2023-12-31 | €132.29 Million ≈ $154.66 Million |
-13.94% |
| 2022-12-31 | €153.71 Million ≈ $179.71 Million |
-3.96% |
| 2021-12-31 | €160.06 Million ≈ $187.12 Million |
+5.68% |
| 2020-12-31 | €151.45 Million ≈ $177.06 Million |
-17.67% |
| 2019-12-31 | €183.94 Million ≈ $215.05 Million |
-35.23% |
| 2018-12-31 | €283.98 Million ≈ $332.00 Million |
+67.97% |
| 2017-12-31 | €169.07 Million ≈ $197.66 Million |
-13.48% |
| 2016-12-31 | €195.41 Million ≈ $228.45 Million |
-16.45% |
| 2015-12-31 | €233.89 Million ≈ $273.44 Million |
+1355.98% |
| 2014-12-31 | €16.06 Million ≈ $18.78 Million |
+3.00% |
| 2013-12-31 | €15.60 Million ≈ $18.23 Million |
-37.44% |
| 2012-12-31 | €24.93 Million ≈ $29.15 Million |
-25.54% |
| 2011-12-31 | €33.48 Million ≈ $39.15 Million |
+131.02% |
| 2010-12-31 | €14.49 Million ≈ $16.95 Million |
-15.22% |
| 2009-12-31 | €17.10 Million ≈ $19.99 Million |
-12.42% |
| 2008-12-31 | €19.52 Million ≈ $22.82 Million |
+44.10% |
| 2007-12-31 | €13.55 Million ≈ $15.84 Million |
+5.13% |
| 2006-12-31 | €12.89 Million ≈ $15.07 Million |
+174.05% |
| 2005-12-31 | €4.70 Million ≈ $5.50 Million |
+4.51% |
| 2004-12-31 | €4.50 Million ≈ $5.26 Million |
-14.63% |
| 2003-12-31 | €5.27 Million ≈ $6.16 Million |
-- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more